126 filings
Page 5 of 7
20-F
adu4lttl m9tfzsy8o
5 Mar 21
Annual report (foreign)
4:01pm
6-K
c6yvmit hn
17 Feb 21
Top-line Data Anticipated by Year End 2021
6:45am
6-K
waxmv
10 Feb 21
PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
4:02pm
6-K
17wrbh47 zs
22 Dec 20
PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program
8:42am
6-K
4xmsi3s2c6
16 Dec 20
Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021
9:07am
6-K
0kqqgbd7ivd9h
24 Nov 20
PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX100for the Prevention of Surgical Site Infections in Colorectal Surgery
4:02pm
6-K
6gdix
12 Nov 20
PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results
6:05am
6-K
j0d7d7oozv43y
19 Aug 20
PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results
8:37am
6-K
euf4gnn9287fx
3 Aug 20
PolyPid granted Fast Track Designation from FDA for D-PLEX100
4:00pm
6-K
mm5at9hn3zg85mqsum4
1 Jul 20
PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:11pm
S-8
t6scejwlzj
29 Jun 20
Registration of securities for employees
7:48am
424B4
51t0qhugzwa05xhya
29 Jun 20
Prospectus supplement with pricing info
12:00am
EFFECT
4dt rf01l82lwv
26 Jun 20
Notice of effectiveness
12:15am
F-1MEF
5pe9dix yjvlq32
25 Jun 20
Registration statement to add securities to prior F-1 registration
6:34pm
CERT
dgqs5k1pdqtvg73
24 Jun 20
Certification of approval for exchange listing
5:05pm
CORRESP
bbt3eg w4lisu
23 Jun 20
Correspondence with SEC
12:00am
CORRESP
qi71j7bvgv8ug6qnm8
23 Jun 20
Correspondence with SEC
12:00am
F-1/A
e6dmd7krga36sko4ja
22 Jun 20
Registration statement (foreign) (amended)
7:18am
CORRESP
opx7udyp ujxme9gpi
22 Jun 20
Correspondence with SEC
12:00am
8-A12B
ojysu
18 Jun 20
Registration of securities on exchange
4:10pm